Orchid Pharma (NSE/BSE), Chennai-based, a leading pharmaceutical company catering across the pharmaceutical value chain (discovery to delivery) with expertise in R&D and marketing, announced the formation of Orchid AMS (Antimicrobial Solutions), a dedicated division focused on helping address the critical challenge of Antimicrobial Resistance (AMR) in India. This strategic move aims to address the growing threat of Antimicrobial Resistance (AMR) in India and globally through innovative products, comprehensive support programs, and digital solutions.
Orchid AMS will spearhead the company’s efforts to combat AMR through a comprehensive approach encompassing innovative product development, robust support programs, and advanced digital solutions. The new entity aims to partner with over 2,500-3,000 hospitals and healthcare institutions in the next two to three years, to implement effective antimicrobial stewardship programs (AMSPs).
To mark this significant initiative, the company is hosting / facilitating a series of sessions aimed at providing a platform for healthcare professionals, policymakers, and industry experts to engage in crucial discussions on AMR and the role of antimicrobial stewardship. In the first phase of its outreach, Orchid AMS will cover Delhi, Mumbai, Bangalore, Chennai, Hyderabad, Vishakapatanam, Coimbatore, Kochi, Thiruvanthapuram, Ahmedabad, Pune, Jaipur, Chandigarh.
With AMS, Orchid Pharma aims to be the preferred knowledge partner for hospitals, committed to ethical practices and enhancing hospital capacity in tackling AMR. The mission is to build a sustainable business while positively impacting society by helping hospitals reduce healthcare-associated infections (HAIs), AMR, and average length of stay (ALOS) through improved clinical outcomes.
Manish Dhanuka, Managing Director, Orchid Pharma, said, “The launch of Orchid AMS is a proof of our commitment to addressing the urgent public health threat posed by AMR. By combining our expertise in antimicrobials and our USFDA-approved manufacturing capabilities, we aim to make a significant impact on combating this public health crisis in India and beyond, said Manish Dhanuka, Managing Director of Orchid Pharma.
Rajnish Rohatgi, Chief Executive Officer, Orchid AMS added, “AMR is one of the biggest healthcare challenges today, and governments across the world including India have launched programs to address it. It's a complex issue requiring a multi-faceted approach, to impact patient compliance, ease of availability without prescriptions, use in crop and livestock farming, and use in hospitals. We wish to be the change we want to see – and commit to responsible promotion of anti-biotics, i.e. 1st Do No harm. Orchid AMS invites leading pharmaceutical companies to join us in this task – to collaborate, even while we compete – and work with healthcare providers, policymakers, and other stakeholders to develop and implement effective ,strategies to combat this growing threat.”